AiCuris Anti-infective Cures AG - Clear Focus on Anti-Infective Cures

2021-11-16

EBMT Transplant Complications Working Party Educational Meeting (virtual) 19 Nov 2021

Listen to the talks of Dr. Alexander Birkmann, AiCuris and Prof. Margeret Kingston, Manchester University NHS Foundation Trust discussing the burden of HSV infections in immunocompromised patients and the need for novel approaches to address foscarnet as well as acyclovir- & foscarnet-resistance.

2021-10-22

AiCuris announces expansion of its collaboration with Lysando with a focus on diabetic foot infections

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin®-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.

2021-10-07

AiCuris announces opening of second round of AiCubator corporate innovation accelerator initiative to propel anti-infective drug development

AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, today announced the opening of the second round of its AiCubator corporate innovation accelerator initiative.

2021-09-20

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Start of a pilot study with immunomodulator AIC649 for treatment of asymptomatic or mildly symptomatic COVID-19-patients to prevent more severe symptoms including respiratory failure that may develop with progression of the disease.

2021-09-17

AiCuris befürwortet und unterstützt die Nationale Allianz für Pandemie-Therapeutika (NA-PATH)

NA-PATH ist eine Initiative des Helmholtz-Zentrums für Infektionsforschung (HZI) und des Deutschen Zentrums für Infektionsforschung (DZIF), die einen Sektor-übergreifenden Ansatz vorschlägt, um auf zukünftige Pandemien durch virale Erreger vorbereitet zu sein.

2021-07-08

AiCuris starts its first pivotal clinical phase 3 trial with pritelivir for the treatment of herpes simplex virus infections in immunocompromised subjects based on efficacy and safety data from a phase 2 trial

Start of pivotal phase 3 development with its proprietary lead compound pritelivir, a novel helicase-primase inhibitor, following encouraging phase 2 interim results achieved in the phase 2 part of its clinical phase 2/3 trial, PRIOH-1.

2021-05-25

AiCuris AG Announces Dr. Stefan Oschmann, Former Merck CEO, to Chair the AiCuris Supervisory Board

The Supervisory Board appointed Dr. Stefan Oschmann as Chairman. He succeeds Helmut Jeggle, Chief Executive Officer of Salvia GmbH, who stepped down as planned from his role as Interim-Chairman of the initial Supervisory Board of AiCuris AG

2021-03-30

AiCuris expands its Management with Prof. Dr. Hubert Trübel joining as Chief Medical Officer and the Appointment of Dr. Tamara Pfaff, Head of Preclinical Development, to the Management Team

Prof. Hubert Trübel joined AiCuris as Head of Clinical Development and Chief Medical Officer. In addition, the Head of Preclinical Development, Dr. Tamara Pfaff, was also appointed to the management team effective April 1, 2021

2021-02-01

AiCuris changes its legal form: AiCuris Anti-infective Cures GmbH becomes AiCuris AG

Transition will support the Company in exploring additional opportunities for future growth

2021-01-13

AiCuris selects three novel anti-infective treatment approaches as winners of the AiCubator Resident Status, a corporate innovative accelerator initiative

2020-12-02

AiCuris receives approval from BfArM to initiate Compassionate Use Program for Pritelivir in Germany

Approval from the German “Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)” to initiate a Compassionate Use Program (Härtefallprogramm) for pritelivir.

2020-08-17

AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference

AiCuris has launched a four-pillar program, “PREP – Pandemic and Resistance Emergency Preparedness”

2020-12-02

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

„Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“

The Powerhouse for Anti-infectives

Committed to making the difference

Fighting infectious diseases of the 21st century

Our innovative Pipeline

Expanding our Portfolio